127 related articles for article (PubMed ID: 16178727)
1. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors.
Bolós J
Mini Rev Med Chem; 2005 Sep; 5(9):857-68. PubMed ID: 16178727
[TBL] [Abstract][Full Text] [Related]
2. Recent developments of p38α MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds.
Kong TT; Zhang CM; Liu ZP
Curr Med Chem; 2013; 20(15):1997-2016. PubMed ID: 23317165
[TBL] [Abstract][Full Text] [Related]
3. p38 MAP kinase inhibitors as anti inflammatory agents.
Amir M; Somakala K; Ali S
Mini Rev Med Chem; 2013 Dec; 13(14):2082-96. PubMed ID: 24107108
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
5. p38 Mitogen-activated protein kinase inhibitors: a review on pharmacophore mapping and QSAR studies.
Gangwal RP; Bhadauriya A; Damre MV; Dhoke GV; Sangamwar AT
Curr Top Med Chem; 2013; 13(9):1015-35. PubMed ID: 23651481
[TBL] [Abstract][Full Text] [Related]
6. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
[TBL] [Abstract][Full Text] [Related]
7. Successful structure-based design of recent p38 MAP kinase inhibitors.
Karcher SC; Laufer SA
Curr Top Med Chem; 2009; 9(7):655-76. PubMed ID: 19689372
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
9. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
12. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase.
Peifer C; Wagner G; Laufer S
Curr Top Med Chem; 2006; 6(2):113-49. PubMed ID: 16454763
[TBL] [Abstract][Full Text] [Related]
13. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.
Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J
Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of bi-thiazole-2,2'-diamines as kinase inhibitory scaffolds.
Ngoei KR; Ng DC; Gooley PR; Fairlie DP; Stoermer MJ; Bogoyevitch MA
Biochim Biophys Acta; 2013 Jun; 1834(6):1077-88. PubMed ID: 23410953
[TBL] [Abstract][Full Text] [Related]
15. Insight into the structural determinants of imidazole scaffold-based derivatives as p38 MAP kinase inhibitors by computational explorations.
Huang C; Li Y; Ren H; Wang J; Shao L; Zhang S; Li G; Yang L
Curr Med Chem; 2012; 19(23):4024-37. PubMed ID: 22680637
[TBL] [Abstract][Full Text] [Related]
16. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008.
Pettus LH; Wurz RP
Curr Top Med Chem; 2008; 8(16):1452-67. PubMed ID: 18991731
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors.
Kulkarni RG; Laufer S; Mangannavar C; Garlapati A
Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566
[TBL] [Abstract][Full Text] [Related]
18. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes.
Natarajan SR; Doherty JB
Curr Top Med Chem; 2005; 5(10):987-1003. PubMed ID: 16178742
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
Kim DK; Lim JH; Lee JA; Dewang PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
[TBL] [Abstract][Full Text] [Related]
20. Small molecular anti-cytokine agents.
Wagner G; Laufer S
Med Res Rev; 2006 Jan; 26(1):1-62. PubMed ID: 16283677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
